CompoAtlas

NeoStrata HQ Plus Lightening Gel

Originaltext auf Französisch.

NeoStrata HQ Plus Lightening Gel, 02245719: in Kanada zugelassenes Naturgesundheitsprodukt. Medizinische Inhaltsstoffe: Hydroquinone.

Die Analyse oraler Dosen ist ohne einen nachgewiesenen ausschließlich oralen Verabreichungsweg nicht anwendbar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut Quelle
Hydroquinone4 % (p/p)

Nicht arzneiliche Inhaltsstoffe

Ammonia Solution, Strong NF, Chlorure de benzalkonium, Ethoxydiglycol, Eau, Hydroxyethyl Cellulose, Métabisulfite de sodium, Éthanol, Gluconolactone, Acide glycolique, propylèneglycol

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 20 ansNon préciséeminimum : 1 Tous les jours ; maximum : 2 Tous les jours

In Kanada zugelassene Verwendungen

Lightens age spots and hyperpigmentation.

Originaltext auf Französisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Précautions et mises en garde : To be used on the advice of a physician. For external use only. Use only as directed. Do not apply over sunburn or irritated skin. Do not apply over sunburn or irritated skin. Avoid contact with eyes, mucous membranes and broken or irritated skin. In case of contact, rinse thoroughly with water. Test for sensitivity. Apply only to small skin surface area. Discontinue use and consult a physician in case of skin reactions or a blue-black darkening of the skin. A mild transient stinging or minor redness may occur in people with sensitive skin. To test for sensitivity, before treatment, apply to area of approximately 1 cm2 of unbroken skin on the inside of the arm. If no irritations occurs within 24 hours, begin treatment for up to 12 weeks. Discontinue use in case of irritation, rash, excessive inflammatory response or if a gradual blue-black darkening of the skin (exogenous ochronosis) occurs. Minor redness is acceptable, but when there is an excessive irritation, a rash or other reaction, further treatment is not advised. Severe itching or reddening may occur, in which case the product should be discontinued and the physician notified immediately. This product contains glycolic acid, an alpha-hydroxy acid (AHA), which may increase skin's sensitivity to the sun and particularly the possibility of sunburn. Limit sun exposure and apply a sunburn protectant while using this product and for a week afterwards. The safety of topical hydroquinone use during pregnancy or for children 12 years or less has not been established. Do not use this product if you have used it or any of its ingredients before and skin sensitivity or irritation has occurred. Do not use this product if you are nursing, pregnant or if you intended to become pregnant within 3 months of use. If you have a family history or, have or have had or are at risk of developing cancer, do not use. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of the insert before prescribing or dispensing this product. Close patient supervision is recommended. A bitter taste and anesthetic effect may occur if applied to the lips. Sunscreen use is essential aspect of hydroquinone therapy because even minimal sunlight exposure may cause skin re-darkening. Treatment should be limited to relatively small areas of the body at one time. Keep out of reach of children. Not for use on children under 12 years of age. In case of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately. Note: Slight darkening of the product is normal when exposed to air and does not affect its potency. When this happens, extract a tiny amount of product, clean with a cotton swab and discard prior to use. If the entire content becomes brown, discontinue use and consult a physician. Store at room temperature.

Originaltext auf Französisch.

Produktdaten

Inhaber
Opella Canada Inc.
NPN oder DIN-HM
02245719
Status
Lizenz nicht aktiv
Lizenzdatum
17. Dezember 2007
Überarbeitungsdatum
21. Februar 2014
Form
Gel
Verabreichungsweg
Topique
Art des Antrags
DIN de transition

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 02245719

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2014. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile